Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Anti-CD19-CAR by Kecellitics Biotech for B-Cell Leukemia: Likelihood of Approval
Anti-CD19-CAR is under clinical development by Kecellitics Biotech and currently in Phase I for B-Cell Leukemia. According to GlobalData, Phase...
Data Insights
Anti-CD22-CAR by Kecellitics Biotech for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Anti-CD22-CAR is under clinical development by Kecellitics Biotech and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...